On October 1, Moderna, Inc. fell 3.1% in pre-market trading, trading at approximately $186.55/share, extending the prior session's sharp decline.

The sell-off continues to be driven by Citi analyst Geoff Meacham's downgrade of Moderna from Neutral to Sell, issued the previous day. While Meacham raised his price target to $80 from $60, the revised target still implies roughly 60% downside from recent trading levels. The analyst noted difficulty justifying the current valuation through public-company comparisons or pipeline net present value. The downgrade carries particular weight as Moderna had previously held only two sell ratings among approximately two dozen covering analysts, making Citi's move a meaningful shift in institutional consensus.

Notably, Rothschild & Co Redburn had already downgraded Moderna to Sell in early September with an $81 target. The Wall Street average target price stands at $112.72, significantly below the current stock price. Although Moderna shares have surged more than fivefold year-to-date — fueled by positive Phase 3 data for its personalized cancer vaccine intismeran autogene — the widening valuation gap between market price and analyst targets continues to intensify selling pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)